开能健康(300272) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 328,165,726.15, representing a 63.33% increase compared to CNY 200,922,590.35 in the same period last year[7]. - Net profit attributable to shareholders reached CNY 25,325,231.55, a significant increase of 2,816.89% from CNY 868,225.96 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was CNY 22,582,688.74, up 1,215.06% from CNY 1,717,238.15 in the previous year[7]. - Basic earnings per share were CNY 0.0443, reflecting a 2,853.33% increase from CNY 0.0015 in the previous year[7]. - The company achieved total revenue of 328.17 million yuan in Q1 2021, a year-on-year increase of 63.33%[18]. - Net profit attributable to shareholders reached 25.33 million yuan, a significant increase of 2,816.89% compared to the same period last year[18]. - The net profit excluding non-recurring gains and losses was 22.58 million yuan, up 1,215.06% year-on-year, driven by improved management efficiency and cost control[18]. - The company reported a total comprehensive income of CNY 30,982,967.44 for Q1 2021, compared to CNY 4,612,070.79 in Q1 2020, marking an increase of approximately 572.5%[56]. - The total profit before tax for Q1 2021 was CNY 35,320,440.28, a substantial increase from CNY 3,045,541.15 in Q1 2020, reflecting a growth of approximately 1,058.5%[56]. Cash Flow - The net cash flow from operating activities was CNY 28,443,512.37, a 415.60% increase compared to a negative cash flow of CNY 9,012,489.60 in the same period last year[7]. - The cash flow from operating activities was CNY 321,554,549.70, compared to CNY 219,576,898.68 in the previous period, indicating a strong cash generation capability[61]. - Total cash inflow from operating activities reached ¥334,404,177.61, up from ¥227,632,515.73 in the previous year, indicating a growth of approximately 47%[63]. - The net cash flow from operating activities for Q1 2021 was ¥28,443,512.37, a significant improvement compared to a net outflow of ¥9,012,489.60 in Q1 2020, representing a turnaround of over 415%[63]. - The ending balance of cash and cash equivalents was ¥149,401,348.09, compared to ¥103,419,002.60 at the end of Q1 2020, marking an increase of approximately 44.5%[64]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,905,681,616.35, a 4.80% increase from CNY 1,818,405,772.85 at the end of the previous year[7]. - The company's current assets totaled CNY 690,102,722.70, slightly up from CNY 679,287,439.15 at the end of 2020, indicating a growth of about 2.4%[45]. - The total liabilities increased to CNY 690,102,722.70, up from CNY 679,287,439.15, reflecting a growth of about 1.2%[45]. - The total liabilities as of March 31, 2021, were CNY 679,775,173.60, compared to CNY 601,901,272.25 at the end of 2020, showing an increase in financial obligations[48]. - Total equity reached CNY 1,216,504,500.60, remaining stable compared to the previous reporting period[70]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,841[11]. - The largest shareholder, Qu Jianguo, holds 38.25% of the shares, totaling 220,638,209 shares[11]. - Kaineng Health's shareholding in Yuaneng Group increased from 15.1% to 19.98% following a capital reduction by Yuaneng Group[32]. Research and Development - R&D expenses increased by 87.63% to approximately 5.10 million yuan, reflecting the company's commitment to new product development[22]. - Research and development expenses for the quarter were CNY 6,192,400.52, up from CNY 3,709,000.16 in the previous year, reflecting a 67.0% increase[58]. Strategic Initiatives - The company plans to continue expanding its overseas market presence and launching new products to capitalize on the recovery in consumer demand[27]. - The company is committed to using repurchased shares for employee stock ownership plans or equity incentives[32]. - The company maintains a focus on strategic investments and partnerships to enhance its market position and operational capabilities[32]. Share Buyback Plans - The company initiated a share buyback plan with a budget of up to 30 million RMB, with a minimum of 15 million RMB, to repurchase A-shares at a price not exceeding 7.00 RMB per share[32]. - As of March 31, 2021, the total number of shares repurchased was 5,784,220, representing 1.003% of the company's total share capital[33]. - A second share buyback plan was approved with a budget of up to 30 million RMB, with a minimum of 20 million RMB, and a price cap of 7.50 RMB per share[33]. - The first buyback was executed between August 2020 and January 2021, with a total expenditure of approximately 29.99 million RMB[33]. Compliance and Governance - The company reported no violations regarding external guarantees during the reporting period[38]. - There were no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[39]. - The company did not engage in any research, communication, or interview activities during the reporting period[40].